Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing

Antimicrob Agents Chemother. 2014 Aug;58(8):4697-702. doi: 10.1128/AAC.03214-14. Epub 2014 Jun 2.

Abstract

In immunosuppressed hosts, the development of multidrug resistance complicates the treatment of cytomegalovirus (CMV) infection. Improved genotypic detection of impending drug resistance may follow from recent technical advances. A severely T-cell-depleted patient with chronic lymphocytic leukemia developed CMV pneumonia and high plasma viral loads that were poorly responsive to antiviral therapy. Serial plasma specimens were analyzed for mutant viral populations by conventional and high-throughput deep-sequencing methods. Uncharacterized mutations were phenotyped for drug resistance using recombinant viruses. Conventional genotyping detected viruses with the UL97 kinase substitution C607Y after ganciclovir treatment, a transient subpopulation of UL54 polymerase L773V mutants first detected 8 weeks after foscarnet was started, and a subpopulation of a mutant with deletion of UL54 codons 981 and 982 2 months after the addition of cidofovir. Deep sequencing of the same serial specimens revealed the same UL54 mutants sooner, along with a more complex evolution of known and newly recognized mutant subpopulations missed by conventional sequencing. The UL54 exonuclease substitutions D413N, K513R, and C539G were newly shown to confer ganciclovir-cidofovir resistance, while L773V was shown to confer foscarnet resistance and add to the ganciclovir resistance conferred by UL97 C607Y. Increased sequencing depth provided a more timely and detailed diagnosis of mutant viral subpopulations that evolved with changing anti-CMV therapy.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Cidofovir
  • Cytomegalovirus / drug effects
  • Cytomegalovirus / genetics*
  • Cytomegalovirus / immunology
  • Cytomegalovirus Infections / diagnosis*
  • Cytomegalovirus Infections / drug therapy
  • Cytomegalovirus Infections / immunology
  • Cytomegalovirus Infections / virology
  • Cytosine / analogs & derivatives
  • Cytosine / therapeutic use
  • DNA-Directed DNA Polymerase / genetics*
  • DNA-Directed DNA Polymerase / metabolism
  • Drug Resistance, Viral
  • Foscarnet / therapeutic use
  • Ganciclovir / therapeutic use
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Immunocompromised Host*
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell / immunology
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • Leukemia, Lymphocytic, Chronic, B-Cell / virology
  • Male
  • Middle Aged
  • Mutation*
  • Organophosphonates / therapeutic use
  • Pneumonia, Viral / diagnosis*
  • Pneumonia, Viral / drug therapy
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / virology
  • Time Factors
  • Viral Proteins / genetics*
  • Viral Proteins / metabolism
  • Virus Replication / drug effects
  • Virus Replication / genetics

Substances

  • Antiviral Agents
  • Organophosphonates
  • UL54 protein, Human herpesvirus 5
  • Viral Proteins
  • Foscarnet
  • Cytosine
  • DNA-Directed DNA Polymerase
  • Cidofovir
  • Ganciclovir